Elion Therapeutics
PrivateLast Round
Series B
Jun 17, 2024
Est. Valuation
$163M
Total Funding Raised
$81M
Company Overview
Elion Therapeutics is a biotechnology company that develops next-generation polyene antifungal therapies to treat life-threatening invasive fungal infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Elion Therapeutics Comparables
Compare Elion Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| F2G | 83% | |
| Matinas BioPharma Holdings, Inc. | 81% | |
| Appili Therapeutics Inc. | 79% |
Elion Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 17, 2024 | ||||
| Seed | Jan 1, 2019 |
Key People
Founding team and executive leadership
Elion Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Seed, Series A, Series B |
| AMR Action Fund | Series B |
| University of Illinois Foundation | Series B |
| Illinois Ventures | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 15, 2026
Phase 2 study started for Turletricin (EL219) for invasive mould infections.
- Jun 17, 2024
$81M round led by Deerfield Management
Elion Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Elion Therapeutics's valuation, stock price, and market status.
Is Elion Therapeutics a public or private company?
Elion Therapeutics is a private company.
What is the current stock price of Elion Therapeutics?
Elion Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Elion Therapeutics worth (valuation)?
Elion Therapeutics's valuation is estimated at $163.0M based on funding round data.
Can I buy Elion Therapeutics stock?
Elion Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Elion Therapeutics's last funding round?
Elion Therapeutics's most recent funding round was Series B on June 17, 2024.
Who are the main investors in Elion Therapeutics?
Key investors in Elion Therapeutics include Deerfield Management.
Will Elion Therapeutics IPO soon?
No public IPO plans have been announced for Elion Therapeutics.
How can I track Elion Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Elion Therapeutics's secondary market activity and sign up for updates.